Salvage immunotherapy viable for non-small cell lung cancer – Healio
|
Salvage immunotherapy viable for non-small cell lung cancer
Healio The question of how long salvage treatment with immunotherapy should be continued had not been established. The CheckMate-153 trial included 220 patients with NSCLC who received 1 year of nivolumab treatment. Researchers randomly assigned patients to … |
